Joy Bessenger
Director of Finance/CFO presso TRELLUS HEALTH PLC
Profilo
Joy Bessenger is currently the Chief Financial Officer at Trellus Health Plc since 2023.
Prior to this, she worked as the Senior Vice President-Corporate Strategy at IMV, Inc. from 2021 to 2022.
Before that, she was the Director-Investor Relations at deCODE genetics, Inc. Ms. Bessenger completed her undergraduate degree at the University of South Florida.
Posizioni attive di Joy Bessenger
| Società | Posizione | Inizio |
|---|---|---|
| TRELLUS HEALTH PLC | Director of Finance/CFO | 18/09/2023 |
Precedenti posizioni note di Joy Bessenger
| Società | Posizione | Fine |
|---|---|---|
| IMV INC. | Investor Relations Contact | 11/06/2022 |
deCODE genetics, Inc.
 deCODE genetics, Inc. Pharmaceuticals: GenericHealth Technology deCODE genetics, Inc. is a bio-pharmaceutical company. It developing and marketing products to improve the treatment, diagnosis and prevention of common diseases. deCODE applies its capabilities in chemistry and structural biology to the development of drugs in major therapeutic areas, and applies its discoveries in human genetics to bring to market DNA-based reference laboratory tests and consumer genome analysis services to assess individual risk of common diseases. The company was founded by Kari Stefansson and Jeffrey Gulcher in August 1996 and is headquartered in Reykjavík, Iceland. | Public Communications Contact | - |
Formazione di Joy Bessenger
| University of South Florida | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| IMV INC. | Health Technology |
| TRELLUS HEALTH PLC | Technology Services |
| Aziende private | 1 |
|---|---|
deCODE genetics, Inc.
deCODE genetics, Inc. Pharmaceuticals: GenericHealth Technology deCODE genetics, Inc. is a bio-pharmaceutical company. It developing and marketing products to improve the treatment, diagnosis and prevention of common diseases. deCODE applies its capabilities in chemistry and structural biology to the development of drugs in major therapeutic areas, and applies its discoveries in human genetics to bring to market DNA-based reference laboratory tests and consumer genome analysis services to assess individual risk of common diseases. The company was founded by Kari Stefansson and Jeffrey Gulcher in August 1996 and is headquartered in Reykjavík, Iceland. | Health Technology |
- Borsa valori
- Insiders
- Joy Bessenger
